ATE422494T1 - Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung - Google Patents
Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkungInfo
- Publication number
- ATE422494T1 ATE422494T1 AT00978215T AT00978215T ATE422494T1 AT E422494 T1 ATE422494 T1 AT E422494T1 AT 00978215 T AT00978215 T AT 00978215T AT 00978215 T AT00978215 T AT 00978215T AT E422494 T1 ATE422494 T1 AT E422494T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridazines
- inhibiting effect
- substituted pyridines
- angiogenesis inhibiting
- angiogenesis
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000004892 pyridazines Chemical class 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40760099A | 1999-09-28 | 1999-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE422494T1 true ATE422494T1 (de) | 2009-02-15 |
Family
ID=23612752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00978215T ATE422494T1 (de) | 1999-09-28 | 2000-09-26 | Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1228063B1 (https=) |
| JP (1) | JP4919567B2 (https=) |
| KR (3) | KR100895571B1 (https=) |
| CN (3) | CN100422172C (https=) |
| AR (3) | AR025752A1 (https=) |
| AT (1) | ATE422494T1 (https=) |
| AU (1) | AU782820B2 (https=) |
| BG (1) | BG65860B1 (https=) |
| BR (1) | BRPI0014382B8 (https=) |
| CA (1) | CA2385817C (https=) |
| CO (1) | CO5200835A1 (https=) |
| CZ (1) | CZ304767B6 (https=) |
| DE (1) | DE60041548D1 (https=) |
| DO (1) | DOP2000000070A (https=) |
| EE (1) | EE05258B1 (https=) |
| ES (1) | ES2320525T3 (https=) |
| GT (1) | GT200000158A (https=) |
| HR (1) | HRP20020308A2 (https=) |
| HU (1) | HU230223B1 (https=) |
| IL (3) | IL148880A0 (https=) |
| MA (1) | MA25563A1 (https=) |
| MX (1) | MXPA02003156A (https=) |
| MY (3) | MY143580A (https=) |
| NO (1) | NO20021520L (https=) |
| NZ (1) | NZ518589A (https=) |
| PA (1) | PA8503201A1 (https=) |
| PE (1) | PE20010607A1 (https=) |
| PL (1) | PL205957B1 (https=) |
| RS (1) | RS50369B (https=) |
| RU (1) | RU2260008C2 (https=) |
| SK (1) | SK287417B6 (https=) |
| TW (1) | TW593315B (https=) |
| UA (1) | UA75053C2 (https=) |
| WO (1) | WO2001023375A2 (https=) |
| ZA (1) | ZA200202760B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012227A2 (en) * | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| WO2003059354A2 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| CA2518530A1 (en) * | 2003-03-11 | 2004-09-23 | Novartis Ag | Use of isoquinoline derivatives for treating cancer and map kinase related diseases |
| WO2004089412A1 (ja) * | 2003-04-08 | 2004-10-21 | Mitsubishi Pharma Corporation | 特異的ｎａｄ(ｐ)ｈオキシダーゼ抑制剤 |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| KR100553398B1 (ko) * | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| WO2006030947A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| WO2007118602A1 (en) * | 2006-04-15 | 2007-10-25 | Bayer Healthcare Ag | Compounds for treating pulmonary hypertension |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CN101481380B (zh) * | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN103396361B (zh) * | 2013-07-24 | 2016-05-04 | 中国人民解放军第二军医大学 | 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用 |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CN104804008B (zh) * | 2015-03-27 | 2016-03-23 | 亿腾药业（泰州）有限公司 | 一种工业化生产甲磺酸特拉替尼的方法 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CN107129502B (zh) | 2017-04-13 | 2022-08-05 | 泰州亿腾景昂药业股份有限公司 | EOC315 Mod.I晶型化合物及其制备方法 |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| US12421228B2 (en) * | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN112830932B (zh) * | 2020-12-25 | 2022-04-08 | 泰州亿腾景昂药业股份有限公司 | 特拉替尼的游离碱晶型及其制备方法与用途 |
| AU2022379973A1 (en) | 2021-11-08 | 2024-06-27 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1453897A (fr) * | 1965-06-16 | 1966-07-22 | Dérivés du thiophène et de thiéno pyridazines | |
| GB1094044A (en) * | 1965-07-12 | 1967-12-06 | Vantorex Ltd | Phthalazine derivatives |
| FR1516777A (fr) * | 1966-08-02 | 1968-02-05 | Innothera Lab Sa | Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation |
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| JPH03106875A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―（３―ピリジルメチル）フタラジン誘導体 |
| DE69533057T2 (de) * | 1994-08-09 | 2005-06-16 | Eisai Co., Ltd. | Kondensierte pyridazinverbindungen |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| PT1107964E (pt) * | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| CN1660840A (zh) * | 1999-03-30 | 2005-08-31 | 诺瓦提斯公司 | 治疗炎性疾病的酞嗪衍生物 |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| PT1254138E (pt) * | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
-
2000
- 2000-09-22 DO DO2000000070A patent/DOP2000000070A/es unknown
- 2000-09-22 GT GT200000158A patent/GT200000158A/es unknown
- 2000-09-22 CO CO00072226A patent/CO5200835A1/es active IP Right Grant
- 2000-09-22 AR ARP000104981A patent/AR025752A1/es not_active Application Discontinuation
- 2000-09-25 MY MYPI20051063A patent/MY143580A/en unknown
- 2000-09-25 PE PE2000001004A patent/PE20010607A1/es not_active Application Discontinuation
- 2000-09-25 MY MYPI20051064A patent/MY143377A/en unknown
- 2000-09-25 PA PA20008503201A patent/PA8503201A1/es unknown
- 2000-09-25 TW TW089119700A patent/TW593315B/zh not_active IP Right Cessation
- 2000-09-25 MY MYPI20004467A patent/MY135058A/en unknown
- 2000-09-26 AT AT00978215T patent/ATE422494T1/de not_active IP Right Cessation
- 2000-09-26 JP JP2001526527A patent/JP4919567B2/ja not_active Expired - Lifetime
- 2000-09-26 DE DE60041548T patent/DE60041548D1/de not_active Expired - Lifetime
- 2000-09-26 RU RU2002111414/04A patent/RU2260008C2/ru active
- 2000-09-26 ES ES00978215T patent/ES2320525T3/es not_active Expired - Lifetime
- 2000-09-26 SK SK591-2002A patent/SK287417B6/sk not_active IP Right Cessation
- 2000-09-26 RS YUP-229/02A patent/RS50369B/sr unknown
- 2000-09-26 CN CNB2005101271092A patent/CN100422172C/zh not_active Expired - Lifetime
- 2000-09-26 PL PL366342A patent/PL205957B1/pl unknown
- 2000-09-26 UA UA2002043504A patent/UA75053C2/uk unknown
- 2000-09-26 MX MXPA02003156A patent/MXPA02003156A/es active IP Right Grant
- 2000-09-26 CA CA2385817A patent/CA2385817C/en not_active Expired - Lifetime
- 2000-09-26 NZ NZ518589A patent/NZ518589A/en not_active IP Right Cessation
- 2000-09-26 HU HU0202704A patent/HU230223B1/hu not_active IP Right Cessation
- 2000-09-26 CN CNB008163693A patent/CN100374435C/zh not_active Expired - Lifetime
- 2000-09-26 KR KR1020087021379A patent/KR100895571B1/ko not_active Expired - Lifetime
- 2000-09-26 AU AU15696/01A patent/AU782820B2/en not_active Expired
- 2000-09-26 WO PCT/US2000/026500 patent/WO2001023375A2/en not_active Ceased
- 2000-09-26 IL IL14888000A patent/IL148880A0/xx active IP Right Grant
- 2000-09-26 EE EEP200200161A patent/EE05258B1/xx not_active IP Right Cessation
- 2000-09-26 EP EP00978215A patent/EP1228063B1/en not_active Expired - Lifetime
- 2000-09-26 KR KR1020027003972A patent/KR100890473B1/ko not_active Expired - Lifetime
- 2000-09-26 HR HR20020308A patent/HRP20020308A2/xx not_active IP Right Cessation
- 2000-09-26 CZ CZ2002-1444A patent/CZ304767B6/cs not_active IP Right Cessation
- 2000-09-26 CN CNB2005101271105A patent/CN100422173C/zh not_active Expired - Lifetime
- 2000-09-26 BR BRPI0014382A patent/BRPI0014382B8/pt not_active IP Right Cessation
- 2000-09-26 KR KR1020087021380A patent/KR100895572B1/ko not_active Expired - Lifetime
-
2002
- 2002-03-26 NO NO20021520A patent/NO20021520L/no unknown
- 2002-04-09 ZA ZA200202760A patent/ZA200202760B/xx unknown
- 2002-04-23 BG BG106637A patent/BG65860B1/bg unknown
- 2002-04-26 MA MA26619A patent/MA25563A1/fr unknown
-
2008
- 2008-08-11 IL IL193367A patent/IL193367A/en active IP Right Grant
- 2008-08-11 IL IL193368A patent/IL193368A/en active IP Right Grant
-
2011
- 2011-07-15 AR ARP110102559A patent/AR082232A2/es unknown
- 2011-07-15 AR ARP110102558A patent/AR082231A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE422494T1 (de) | Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung | |
| DE69923869D1 (de) | Substituierte pyridine mit herbizider wirkung | |
| DE69826841D1 (de) | Phthalazines mit angiogenesis-hemmender wirkung | |
| DE60120964D1 (de) | Substituirte pyridine mit herbizider wirkung | |
| ATE194832T1 (de) | 2-aryl-substituierte pyridine | |
| IS6518A (is) | Pyridín, pyrimidín, pyrazín og tríazín setin með arýl og notkun þeirra | |
| ATE249437T1 (de) | Substituierte pyridine als selektive cyclooxygenase inhibitoren | |
| ATE381556T1 (de) | Pyridin-derivate mit ikb-kinase (ikk-beta) hemmender wirkung | |
| DE60302336D1 (de) | Neue pyridin- und quinolin-derivate | |
| DE59710981D1 (de) | Heterocyclisch kondensierte Pyridine als CETP Inhibitoren | |
| DE50305279D1 (de) | 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine | |
| NO995340D0 (no) | Ukonsolidert soneisolasjon og styring | |
| ATE265448T1 (de) | Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung | |
| DE10163359B4 (de) | Pyridinderivat und dessen Komplex | |
| DE69837621D1 (de) | Substituierte pyrimidine und pyridine als unkrautbekämpfungsmittel | |
| DE59102729D1 (de) | Substituierte Pyridine. | |
| DK1068194T3 (da) | PDE IV-hæmmende pyridinderivater | |
| DK1380297T3 (da) | Orale sammensætninger med 8-chlor-6,11-dihydro-11(4-piperidyliden)-5H-benzo[5,6]-cyklo-hepta[1,2-b]pyridin | |
| PT1149096E (pt) | N-oxidos de piridina triciclicos agonistas de vasopressina | |
| ATE271554T1 (de) | Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung | |
| GB9810542D0 (en) | Pyrazine and pyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |